+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immune Repertoire Sequencing Market by Offerings (Instruments, Reagents & Consumables, Software & Services), Technology (Next Generation Sequencing, Sanger Sequencing), Sample Type, Application, End User - Global Forecast 2025-2030- Product Image
Immune Repertoire Sequencing Market by Offerings (Instruments, Reagents & Consumables, Software & Services), Technology (Next Generation Sequencing, Sanger Sequencing), Sample Type, Application, End User - Global Forecast 2025-2030- Product Image
Sale

Immune Repertoire Sequencing Market by Offerings (Instruments, Reagents & Consumables, Software & Services), Technology (Next Generation Sequencing, Sanger Sequencing), Sample Type, Application, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 180 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6159793
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Immune repertoire sequencing has emerged as a transformative force within immunology and personalized medicine. By decoding the diverse landscape of B-cell and T-cell receptors, this technology offers unprecedented insights into immune responses, disease progression, and therapeutic efficacy. Recent advances in high-throughput sequencing platforms and bioinformatic algorithms have accelerated the ability to capture millions of unique receptor sequences, elevating both research discovery and clinical diagnostics.

As the field matures, stakeholders across academia, biotechnology, and pharmaceutical industries are harnessing these capabilities to drive antibody discovery, vaccine design, and biomarker development. Notably, integration with single-cell analysis and machine learning frameworks has expanded the scope of applications from broad immune profiling to deep interrogation of antigen-specific responses.

This introduction sets the stage for a comprehensive examination of the market dynamics shaping immune repertoire sequencing. It establishes the foundational context for assessing emerging paradigms, regulatory impacts, strategic segmentation, regional drivers, and competitive positioning. By framing the current landscape and anticipated challenges, this report equips decision-makers with the depth of understanding required to navigate a rapidly evolving sector.

Emerging Paradigms Reshaping the Sequencing Landscape

The immune repertoire sequencing landscape is undergoing a series of paradigm shifts driven by technological convergence and evolving research demands. Cloud-native bioinformatics platforms now seamlessly integrate with laboratory information management systems, enabling real-time data processing and collaborative workflows across geographically dispersed teams. Moreover, the transition from short-read to long-read sequencing technologies has begun to reduce ambiguity in receptor assembly, delivering improved resolution of full-length variable regions and clonal lineage tracing.

At the same time, turnkey solutions combining automated library preparation with end-to-end analytics have lowered barriers to entry for smaller research laboratories. This democratization of advanced sequencing capabilities is fostering a more inclusive ecosystem, where emerging biotech firms can compete alongside established incumbents.

Furthermore, cross-industry collaborations are accelerating platform adoption in clinical settings. Partnerships between sequencing providers and immunotherapy developers are unlocking new avenues for patient stratification, minimal residual disease monitoring, and personalized vaccine efficacy assessments. As a result, the market is shifting from proof-of-concept studies toward scalable, regulated workflows capable of supporting late-stage clinical trials and routine diagnostic applications.

Assessing the Effects of United States Tariffs on Sequencing in 2025

The imposition of new United States tariffs in 2025 has introduced an additional layer of complexity for global suppliers and end users in the immune repertoire sequencing market. Increased duties on imported sequencing instruments and reagents have elevated capital expenditure requirements for laboratories outside the domestic manufacturing base. In turn, procurement cycles have lengthened as organizations reassess total cost of ownership and supply chain resilience.

This tariff regime has also stimulated a shift toward regional sourcing strategies. Manufacturers are exploring domestic production facilities to mitigate import surcharges and ensure continuity of reagent supplies. At the same time, distributors have begun to adjust pricing models and inventory buffers to accommodate greater cost volatility.

Despite these headwinds, strategic alliances between local OEMs and international technology providers are emerging as a pathway to preserve market momentum. Such collaborations facilitate technology transfers and license arrangements that can partially offset the financial burden of import tariffs. Consequently, while the immediate impact on unit prices and adoption rates is apparent, the industry response underscores a broader trend toward supply chain localization and cooperative innovation.

Unveiling Market Dynamics Across Key Segments

A nuanced examination of market segmentation reveals distinct dynamics that are shaping growth trajectories across multiple dimensions. In terms of offerings, sequencing instruments such as polymerase chain reaction machines and high-throughput sequencers continue to command substantial investments, while the reagents and consumables category-encompassing library preparation kits, multiplex PCR reagents, and sequencing reagents-remains the backbone of day-to-day operations. Complementing these hardware and chemical inputs, software tools for data analysis and end-to-end workflow services are gaining traction as integrators seek to streamline pipelines and enhance reproducibility.

When viewed through the lens of technology, next-generation sequencing platforms dominate due to their scalability and declining per-sample costs, yet Sanger sequencing retains relevance in validation workflows and targeted applications. The choice of sample type-whether bone marrow specimens, peripheral blood samples, or tissue biopsies-drives unique protocol optimizations and influences throughput demands. Meanwhile, applications such as antibody discovery, biomarker identification, immunodeficiency diagnosis, and vaccine research each contribute to a diverse demand profile that informs vendor strategies and service offerings.

Finally, end users ranging from contract research organizations to hospitals, pharmaceutical and biotechnology companies, as well as dedicated research institutes, exhibit varying procurement behaviors and adoption rates. Understanding the interplay between these segments is critical for tailored value propositions, go-to-market models, and service level agreements that address the specific needs of each stakeholder group.

Regional Drivers Steering Market Growth

Regional disparities in infrastructure, funding priorities, and regulatory frameworks are driving differentiated adoption curves for immune repertoire sequencing. In the Americas, robust government support for precision medicine initiatives and a mature genomics ecosystem have fostered widespread implementation in both academic centers and clinical laboratories. North American stakeholders benefit from well-established reimbursement pathways, expediting the translation of research insights into diagnostic solutions.

In Europe, the Middle East and Africa region, harmonized regulatory standards across the European Union have lowered barriers to cross-border collaboration, while targeted investments in research consortia are expanding capacity for large-scale immunoprofiling studies. Nonetheless, variable reimbursement models and fragmented healthcare systems introduce complexity that vendors and end users must navigate.

Across Asia-Pacific, rapid economic development, increasing R&D budgets, and government incentives for biotechnology are fueling adoption in emerging markets. Strategic partnerships between local sequencing providers and international technology firms are enabling technology transfer and skill development, positioning the region as a future growth hotspot for both diagnostic and therapeutic applications of immune repertoire sequencing.

Competitive Landscape and Leading Innovators

The competitive landscape is characterized by a blend of established sequencing giants and specialized innovators. Leading instrument manufacturers maintain their dominance through continuous platform upgrades that enhance throughput, accuracy, and user experience. These firms pair hardware advancements with proprietary bioinformatic suites, creating bundled solutions that lock in long-term service and consumables agreements.

At the same time, a wave of focused players has emerged, offering niche solutions such as high-resolution clonal tracking, single-cell integration modules, and cloud-native analytics designed for hyperscale data processing. These entrants often cultivate partnerships with academic institutions and clinical research organizations to validate their technologies across diverse use cases.

Furthermore, collaborative licensing and co-development agreements are becoming more common as companies seek to expand their IP portfolios and accelerate time to market. Strategic acquisitions of complementary workflow service providers and data analysis platforms underscore a broader industry push toward end-to-end offerings that reduce friction for end users. Ultimately, success in this environment hinges on the ability to deliver interoperable systems, reliable support networks, and flexible commercial models that align with evolving customer requirements.

Strategic Imperatives for Industry Leaders

Industry leaders must adopt a proactive approach to capitalize on emerging opportunities and mitigate evolving risks. Investing in integrated platform development that unites instrumentation, reagents, and analytics will differentiate offerings and foster customer loyalty. Concurrently, forging strategic alliances with regional manufacturers and academic consortia can enhance supply chain resilience and facilitate local market entry.

Moreover, companies should prioritize modular software architectures and open-API frameworks to ensure seamless integration with existing laboratory information systems. This flexibility not only accelerates adoption but also positions providers to capitalize on the increasing demand for multi-omic data convergence. Additionally, engaging with regulatory agencies early in the product development cycle will streamline approval pathways and preempt compliance challenges.

Finally, instituting dynamic pricing models and value-based service agreements can address the budgetary constraints of diverse end users, from contract research organizations to clinical laboratories. By aligning commercial strategies with customer outcomes, organizations will create sustainable revenue streams and fortify their competitive positioning in a rapidly evolving market.

Rigorous Framework Underpinning the Analysis

This analysis is grounded in a rigorous methodology combining comprehensive secondary research with targeted primary engagements. The process began with an exhaustive review of scientific literature, regulatory filings, company white papers, and patent databases. Market participants were then engaged through in-depth interviews, including senior executives at sequencing providers, purchasing managers at end-user institutions, and key opinion leaders in immunology.

Quantitative data was triangulated to enhance reliability, integrating public financial disclosures with proprietary intelligence from supply chain partners. Segmentation analysis was conducted by mapping product portfolios against end-user requirements, application areas, and geographic considerations. Qualitative insights were validated through advisory board consultations and peer benchmarking exercises.

To ensure analytical rigor, each data point underwent multi-layer verification, and model assumptions were stress-tested across plausible market scenarios. The final framework synthesizes both macroeconomic factors and micro-level operational drivers, delivering a holistic view of the immune repertoire sequencing landscape.

Synthesis of Critical Findings and Future Outlook

The immune repertoire sequencing sector stands at a pivotal crossroads, shaped by technological innovation, shifting regulatory landscapes, and evolving customer expectations. Key findings highlight the critical role of integrated solutions, strategic supply chain realignments in response to tariffs, and the importance of modular, interoperable platforms that cater to a broad spectrum of end users.

Regional nuances underscore the necessity for tailored market approaches, with advanced economies demanding seamless regulatory compliance and emerging markets prioritizing cost-effective deployment. Competitive dynamics continue to favor organizations that balance core instrument excellence with differentiated service offerings and agile commercial models.

Looking ahead, the maturation of long-read sequencing, growth in single-cell applications, and convergence with computational immunology will drive the next wave of breakthroughs. Companies that proactively align their R&D roadmaps, partnership strategies, and customer engagement frameworks with these trends will be best positioned to lead the market and unlock new avenues for scientific discovery and clinical impact.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Offerings
    • Instruments
      • PCR Machines
      • Sequencers
    • Reagents & Consumables
      • Library Preparation Kits
      • Multiplex PCR Reagents
      • Sequencing Reagents
    • Software & Services
      • Data Analysis Software
      • Workflow Services
  • Technology
    • Next Generation Sequencing
    • Sanger Sequencing
  • Sample Type
    • Bone Marrow
    • Peripheral Blood
    • Tissue Sample
  • Application
    • Antibody Discovery
    • Biomarker Discovery
    • Immunodeficiency Identification
    • Vaccine Development
  • End User
    • Contract Research Organization
    • Hospital
    • Pharmaceutical & Biotech Companies
    • Research Institute
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Adaptive Biotechnologies Corporation
  • BGI Genomics Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • 10x Genomics, Inc.
  • QIAGEN N.V.
  • Pacific Biosciences of California, Inc.
  • Takara Bio Inc.
  • ArcherDX, Inc.
  • Agilent Technologies, Inc.
  • CD Genomics
  • Creative Biolabs, Inc.
  • Eurofins Genomics
  • F. Hoffmann-La Roche Ltd.
  • GENEWIZ by Azenta Life Sciences
  • Invitae Corp.
  • iRepertoire, Inc.
  • MedGenome Inc.
  • NanoString Technologies, Inc. by Bruker Corporation
  • Paragon Genomics, Inc.
  • Twist Bioscience Corporation

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
3.1. Charting the Rise and Transformative Journey of Immune Repertoire Sequencing
3.2. Decoding Buyer Behavior and Strategic Positioning in Sequencing Platforms
3.3. Lifecycle Stages and Intellectual Property Fortification Roadmap
3.4. Strategic Growth Pathways and Innovation Frontiers in Sequencing
4. Market Overview
4.1. Introduction
4.1.1. Decoding Immunity: Defining Repertoire Sequencing and Its Economic Significance
4.1.2. Regional Dynamics Shaping Immune Repertoire Sequencing Adoption
4.1.3. Innovation and Investment: Recent Advances and Future Trajectories in Immune Profiling
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Application of immune repertoire sequencing in personalized cancer immunotherapy response monitoring
5.1.1. Defining Immune Repertoire Sequencing for Personalized Immunotherapy Monitoring
5.1.2. How Repertoire Sequencing Is Reshaping Cancer Immunotherapy Markets
5.1.3. Anticipating the Next Phase of Immunotherapy Response Tracking
5.2. Industry collaboration on standardizing assay protocols and data reporting in repertoires
5.2.1. Harmonizing Assays and Reporting: Defining Industry Collaboration in Immune Repertoire Sequencing
5.2.2. Redefining Competitive Dynamics Through Shared Protocols and Data Transparency
5.2.3. Navigating Future Pathways and Risks in Standardizing Immune Repertoire Platforms
5.3. Development of high-throughput multiplexed assays for broad-spectrum immune receptor profiling
5.3.1. Decoding High-Throughput Multiplexed Assays in Immune Repertoire Sequencing
5.3.2. How Multiplexed Assays Are Reshaping the Immune Sequencing Landscape
5.3.3. Anticipating the Next Wave of Multiplex Assay Innovations
5.4. Partnerships between sequencing technology providers and biopharma for vaccine antigen discovery
5.4.1. Bridging Sequencing Expertise with Biopharma Vaccine Discovery
5.4.2. Transforming Market Dynamics and Innovation through Deep Partnerships
5.4.3. Charting Future Paths and Mitigating Risks in Sequencing Collaborations
5.5. Integration of single-cell and immune repertoire sequencing for comprehensive immune profiling
5.6. Incorporation of long-read sequencing to obtain full-length TCR and BCR chain sequences
5.6.1. Unlocking Full-Length Adaptive Immune Insights with Long-Read Sequencing
5.6.2. Rewriting the Market Playbook Through Full-Length Receptor Sequencing
5.6.3. Strategic Roadmap for Next-Gen Immune Profiling with Long-Read Technology
5.7. Expansion of clinical-grade immune repertoire sequencing services for autoimmune diagnostics
5.7.1. Defining Clinical-Grade Sequencing Expansion in Autoimmune Diagnostics
5.7.2. How Clinical-Grade Sequencing Is Redefining Market Dynamics
5.7.3. Anticipating Growth Paths and Challenges in Sequencing Services
5.8. Growth of cloud-based bioinformatics pipelines enabling scalable immune repertoire analysis
5.8.1. Cloud-Powered Pipelines Redefining Immune Repertoire Analysis
5.8.2. Disruptive Shifts Driven by Scalable Cloud Bioinformatics
5.8.3. Navigating the Next Wave of Cloud-Based Immune Profiling
5.9. Adoption of AI-driven algorithms for clonotype identification and repertoire diversity analysis
5.9.1. Harnessing Machine Learning to Decode Clonal Complexity
5.9.2. Transforming Market Dynamics Through AI-Enhanced Analytics
5.9.3. Charting the Next Phase of AI-Driven Repertoire Analysis
5.10. Emergence of multiomics platforms combining TCR and BCR sequencing with transcriptomic profiling
5.10.1. Integrating TCR, BCR, and Transcriptome: The Rise of Multiomics in Immune Profiling
5.10.2. Reconfiguring the Immune Sequencing Ecosystem Through Multiomic Convergence
5.10.3. Navigating Future Pathways for Multiomics in Immune Repertoire Analysis
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.1.1. High Barriers Shield Immune Repertoire Sequencing from New Entrants
6.1.2. Substitute Technologies Pose Moderate Pressure on Sequencing Services
6.1.3. Supplier Control of Critical Reagents Elevates Input Power
6.1.4. Sophisticated Buyers Wield Strong Influence on Sequencing Providers
6.1.5. Intense Competition Fuels Innovation in Immune Repertoire Sequencing
6.2. PESTLE Analysis
6.2.1. Shifting Government Policies Driving Sequencing Innovation
6.2.2. Funding Flows and Cost Pressures in Repertoire Sequencing
6.2.3. Patient Awareness and Ethical Expectations Elevating Research Priorities
6.2.4. Next-Gen Tools and AI Accelerating Immune Profiling
6.2.5. Data Privacy and IP Frameworks Influencing Sequencing Operations
6.2.6. Sustainability Demands and Resource Constraints in Sequencing Labs
7. Cumulative Impact of United States Tariffs 2025
7.1. Key Tariffs Shaping US Trade Since 2023
7.2. From Protectionism Roots to Strategic Shields
7.3. Tariff Pressures Amid Rising Prices
7.4. Tit-for-Tat Tariffs and Geopolitical Tensions
7.5. Repercussions for America’s Trading Allies
7.6. Reshaping America’s Economic Landscape
7.7. Bridging Divides with Strategic Policy Solutions
8. Immune Repertoire Sequencing Market, by Offerings
8.1. Introduction
8.2. Instruments
8.2.1. PCR Machines
8.2.2. Sequencers
8.3. Reagents & Consumables
8.3.1. Library Preparation Kits
8.3.2. Multiplex PCR Reagents
8.3.3. Sequencing Reagents
8.4. Software & Services
8.4.1. Data Analysis Software
8.4.2. Workflow Services
9. Immune Repertoire Sequencing Market, by Technology
9.1. Introduction
9.2. Next Generation Sequencing
9.3. Sanger Sequencing
10. Immune Repertoire Sequencing Market, by Sample Type
10.1. Introduction
10.2. Bone Marrow
10.3. Peripheral Blood
10.4. Tissue Sample
11. Immune Repertoire Sequencing Market, by Application
11.1. Introduction
11.2. Antibody Discovery
11.3. Biomarker Discovery
11.4. Immunodeficiency Identification
11.5. Vaccine Development
12. Immune Repertoire Sequencing Market, by End User
12.1. Introduction
12.2. Contract Research Organization
12.3. Hospital
12.4. Pharmaceutical & Biotech Companies
12.5. Research Institute
13. Americas Immune Repertoire Sequencing Market
13.1. Introduction
13.2. Brazil
13.3. United States
13.4. Argentina
13.5. Mexico
13.6. Canada
14. Europe, Middle East & Africa Immune Repertoire Sequencing Market
14.1. Introduction
14.2. Israel
14.3. Russia
14.4. Finland
14.5. Turkey
14.6. United Arab Emirates
14.7. France
14.8. Italy
14.9. South Africa
14.10. Norway
14.11. Sweden
14.12. Saudi Arabia
14.13. Denmark
14.14. Germany
14.15. Egypt
14.16. Nigeria
14.17. Spain
14.18. United Kingdom
14.19. Netherlands
14.20. Poland
14.21. Qatar
14.22. Switzerland
15. Asia-Pacific Immune Repertoire Sequencing Market
15.1. Introduction
15.2. Japan
15.3. Vietnam
15.4. Singapore
15.5. Taiwan
15.6. Thailand
15.7. Australia
15.8. Malaysia
15.9. China
15.10. Philippines
15.11. Indonesia
15.12. India
15.13. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Adaptive Biotechnologies Corporation
16.3.1.1. Dissecting Key Assay Platforms and Market Fit
16.3.1.2. Mitigating Threats and Fortifying Adaptive’s Portfolio
16.3.2. BGI Genomics Co., Ltd.
16.3.2.1. Decoding the Portfolio: Evaluating BGI’s Flagship Immune Sequencing Solutions
16.3.2.2. Navigating Threats and Seizing Opportunities: Strategic Imperatives for BGI Genomics
16.3.3. Thermo Fisher Scientific Inc.
16.3.4. Illumina, Inc.
16.3.5. 10x Genomics, Inc.
16.3.6. QIAGEN N.V.
16.3.6.1. Evolution and Global Footprint of QIAGEN in Immune Repertoire Sequencing
16.3.6.2. Evaluating QIAGEN’s Immune Repertoire Sequencing Portfolio Against Market Needs
16.3.6.3. Navigating Risks and Fortifying QIAGEN’s Position in Immune Repertoire Sequencing
16.3.7. Pacific Biosciences of California, Inc.
16.3.7.1. Assessing PacBio’s Flagship Platforms for Immune Repertoire Profiling
16.3.7.2. Navigating Risks and Strategic Pathways for Future Growth in Immune Sequencing
16.3.8. Takara Bio Inc.
16.3.8.1. Takara Bio’s Strategic Evolution and Global Reach in Immune Repertoire Sequencing
16.3.8.2. Deep Dive into SMARTer Immune Profiling and Competitive Positioning
16.3.8.3. Mitigating Threats and Fortifying Takara Bio’s Repertoire Sequencing Leadership
16.3.9. ArcherDX, Inc.
16.3.9.1. ArcherDX’s Journey from AMP Innovation to Global Immune Profiling Powerhouse
16.3.9.2. Immunoverse™ Platforms: Meeting Research Demands with High-Fidelity Immune Profiling
16.3.9.3. Navigating Competitive Pressures with Single-Cell Integration and AI-Enhanced Analytics
16.3.10. Agilent Technologies, Inc.
16.3.10.1. Forged Through Innovation: Agilent’s Rise in Immune Repertoire Sequencing
16.3.10.2. Precision Tools: Evaluating Agilent’s Flagship Immune Repertoire Offerings
16.3.10.3. Navigating Threats and Seizing Growth: Strategies to Fortify Agilent’s Repertoire Position
16.3.11. CD Genomics
16.3.11.1. CD Genomics: Evolution and Market Footprint
16.3.11.2. Evaluating CD Genomics' Immune Repertoire Sequencing Solutions
16.3.11.3. Navigating Risks and Charting Strategic Paths
16.3.12. Creative Biolabs, Inc.
16.3.12.1. Creative Biolabs’ Strategic Evolution in Immune Repertoire Sequencing
16.3.12.2. Unpacking the Flagship Immune Repertoire Solutions Powering Creative Biolabs’ Growth
16.3.12.3. Addressing Threats and Seizing Strategic Opportunities in Immune Repertoire Sequencing
16.3.13. Eurofins Genomics
16.3.13.1. Eurofins Genomics’ Evolution and Market Leadership in Immune Repertoire Sequencing
16.3.13.2. Deep Dive into Flagship Repertoire Sequencing Services and Their Competitive Edge
16.3.13.3. Navigating Risks and Strategic Pathways for Growth in Immune Profiling
16.3.14. F. Hoffmann-La Roche Ltd.
16.3.14.1. Roche’s Pioneering Journey in Immune Repertoire Sequencing
16.3.14.2. Deep Dive into Roche’s Immune Sequencing Portfolio and Market Fit
16.3.14.3. Navigating Risks and Charting Strategies for Future Growth
16.3.15. GENEWIZ by Azenta Life Sciences
16.3.15.1. From Gene Synthesis Innovator to Immune Repertoire Sequencing Leader
16.3.15.2. Flagship Services Elevating Precision in Immune Repertoire Sequencing
16.3.15.3. Navigating Risks and Strengthening Market Position in Immune Profiling
16.3.16. Invitae Corp.
16.3.16.1. Invitae’s Evolution and Global Footprint in Immune Repertoire Sequencing
16.3.16.2. Assessing Invitae’s Flagship Immune Repertoire Sequencing Solutions
16.3.16.3. Critical Challenges and Strategic Pathways for Invitae in Immune Profiling
16.3.17. iRepertoire, Inc.
16.3.17.1. Flagship Solutions Driving Immune Repertoire Insights
16.3.17.2. Navigating Threats and Forging Strategic Resilience
16.3.18. MedGenome Inc.
16.3.18.1. Deep Dive into MedGenome’s Flagship Immune Profiling Solutions
16.3.18.2. Navigating Risks and Forging Strategies for Immune Sequencing Leadership
16.3.19. NanoString Technologies, Inc. by Bruker Corporation
16.3.19.1. From Digital Profiling Pioneer to Immune Repertoire Powerhouse
16.3.19.2. Flagship Molecular Profilers Redefining Immune Repertoire Analysis
16.3.19.3. Mitigating Strategic Risks to Fortify Future Immune Repertoire Leadership
16.3.20. Paragon Genomics, Inc.
16.3.20.1. Analyzing Paragon Genomics’ Flagship Immune Repertoire Solutions
16.3.20.2. Mitigating Risks and Fortifying Future Market Position
16.3.21. Twist Bioscience Corporation
16.3.21.1. From Synthetic DNA Roots to Immune Profiling Pioneer
16.3.21.2. Dissecting Twist’s Immune Repertoire Sequencing Portfolio
16.3.21.3. Navigating Threats and Charting Growth Pathways
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. IMMUNE REPERTOIRE SEQUENCING MARKET MULTI-CURRENCY
FIGURE 2. IMMUNE REPERTOIRE SEQUENCING MARKET MULTI-LANGUAGE
FIGURE 3. IMMUNE REPERTOIRE SEQUENCING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. IMMUNE REPERTOIRE SEQUENCING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. IMMUNE REPERTOIRE SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. IMMUNE REPERTOIRE SEQUENCING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY LIBRARY PREPARATION KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY MULTIPLEX PCR REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SEQUENCING REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY WORKFLOW SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY PERIPHERAL BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TISSUE SAMPLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY ANTIBODY DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY IMMUNODEFICIENCY IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. MEXICO IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 72. MEXICO IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 73. MEXICO IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 74. MEXICO IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 75. MEXICO IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 76. MEXICO IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 77. MEXICO IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. MEXICO IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 79. CANADA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 80. CANADA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 81. CANADA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 82. CANADA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 83. CANADA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 84. CANADA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 85. CANADA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. CANADA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 96. ISRAEL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 101. ISRAEL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 102. ISRAEL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. ISRAEL IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. RUSSIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 105. RUSSIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 106. RUSSIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. FINLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 113. FINLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 114. FINLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 115. FINLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 116. FINLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 117. FINLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 118. FINLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. FINLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. TURKEY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 121. TURKEY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 122. TURKEY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 123. TURKEY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 124. TURKEY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 125. TURKEY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 126. TURKEY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. TURKEY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 133. UNITED ARAB EMIRATES IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 134. UNITED ARAB EMIRATES IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. UNITED ARAB EMIRATES IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. FRANCE IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 137. FRANCE IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 138. FRANCE IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 139. FRANCE IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 140. FRANCE IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 141. FRANCE IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 142. FRANCE IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. FRANCE IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. ITALY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 145. ITALY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 146. ITALY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 147. ITALY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 148. ITALY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 149. ITALY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 150. ITALY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 151. ITALY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. SOUTH AFRICA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 153. SOUTH AFRICA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 154. SOUTH AFRICA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 155. SOUTH AFRICA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 156. SOUTH AFRICA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 157. SOUTH AFRICA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. NORWAY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 161. NORWAY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 162. NORWAY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 163. NORWAY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 164. NORWAY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 165. NORWAY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 166. NORWAY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 167. NORWAY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. SWEDEN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 169. SWEDEN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 170. SWEDEN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 180. SAUDI ARABIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 181. SAUDI ARABIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 182. SAUDI ARABIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. SAUDI ARABIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. DENMARK IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 185. DENMARK IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 186. DENMARK IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 187. DENMARK IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 188. DENMARK IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 189. DENMARK IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 190. DENMARK IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 191. DENMARK IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 192. GERMANY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 193. GERMANY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 194. GERMANY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 195. GERMANY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 196. GERMANY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 197. GERMANY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 198. GERMANY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. GERMANY IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. EGYPT IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 201. EGYPT IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 202. EGYPT IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 203. EGYPT IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 204. EGYPT IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 205. EGYPT IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 206. EGYPT IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 207. EGYPT IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. SPAIN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 217. SPAIN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 218. SPAIN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 219. SPAIN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 220. SPAIN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 221. SPAIN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 222. SPAIN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 223. SPAIN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. UNITED KINGDOM IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 226. UNITED KINGDOM IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 228. UNITED KINGDOM IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. NETHERLANDS IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 233. NETHERLANDS IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. NETHERLANDS IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. POLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 241. POLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 242. POLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 243. POLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 244. POLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 245. POLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 246. POLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 247. POLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. QATAR IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 249. QATAR IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 250. QATAR IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 251. QATAR IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 252. QATAR IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 253. QATAR IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 254. QATAR IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 255. QATAR IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 273. JAPAN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 274. JAPAN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 275. JAPAN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 276. JAPAN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 277. JAPAN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 278. JAPAN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 279. JAPAN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 280. JAPAN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. VIETNAM IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 282. VIETNAM IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 283. VIETNAM IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 284. VIETNAM IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 285. VIETNAM IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 286. VIETNAM IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 287. VIETNAM IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 288. VIETNAM IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. SINGAPORE IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 290. SINGAPORE IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 291. SINGAPORE IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 292. SINGAPORE IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 293. SINGAPORE IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 294. SINGAPORE IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 295. SINGAPORE IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 296. SINGAPORE IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. TAIWAN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 298. TAIWAN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 299. TAIWAN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 300. TAIWAN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 301. TAIWAN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 302. TAIWAN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 303. TAIWAN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 304. TAIWAN IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 305. THAILAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 306. THAILAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
TABLE 307. THAILAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2030 (USD MILLION)
TABLE 308. THAILAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2030 (USD MILLION)
TABLE 309. THAILAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 310. THAILAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 311. THAILAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 312. THAILAND IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 313. AUSTRALIA IMMUNE REPERTOIRE SEQUENCING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 314. AUSTRALIA IMMUNE REPERTOIRE SEQUEN

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Immune Repertoire Sequencing market report include:
  • Adaptive Biotechnologies Corporation
  • BGI Genomics Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • 10x Genomics, Inc.
  • QIAGEN N.V.
  • Pacific Biosciences of California, Inc.
  • Takara Bio Inc.
  • ArcherDX, Inc.
  • Agilent Technologies, Inc.
  • CD Genomics
  • Creative Biolabs, Inc.
  • Eurofins Genomics
  • F. Hoffmann-La Roche Ltd.
  • GENEWIZ by Azenta Life Sciences
  • Invitae Corp.
  • iRepertoire, Inc.
  • MedGenome Inc.
  • NanoString Technologies, Inc. by Bruker Corporation
  • Paragon Genomics, Inc.
  • Twist Bioscience Corporation

Related Topics

Related Reports

Immune Repertoire Sequencing Market by Product, Technology, Service, Application - Global Forecast to 2030 - Product Image

Immune Repertoire Sequencing Market by Product, Technology, Service, Application - Global Forecast to 2030

  • Report
  • 371 Pages
  • Global
From
Immune Repertoire Sequencing Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Product Type - Product Image

Immune Repertoire Sequencing Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Product Type

  • Report
  • 91 Pages
  • Global
From
Immune Repertoire Sequencing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Immune Repertoire Sequencing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 219 Pages
  • Global
2024 Global Forecast for Immune Repertoire Sequencing Market (2025-2030 Outlook)-High Tech & Emerging Markets Report - Product Image

2024 Global Forecast for Immune Repertoire Sequencing Market (2025-2030 Outlook)-High Tech & Emerging Markets Report

  • Report
  • 132 Pages
  • Global
From
Epigenetic Drug and Diagnostic Technology - Global Strategic Business Report - Product Image

Epigenetic Drug and Diagnostic Technology - Global Strategic Business Report

  • Report
  • 377 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.